Protein biomarkers for multiple sclerosis: Semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 8, 2012, Pages 1081-1091

  Avsar, Timucin ^a   Korkmaz, Didem ^a   Tütüncü, Melih ^b   Demirci, N Onat ^b   Saip, Sabahattin ^b   Kamasak, Mustafa ^a   Siva, Aksel ^b   Turanli, Eda Tahir ^a  

^a ISTANBUL TECHNICAL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Biomarker; cerebrospinal fluid; GFAP; MBP; MOG; multiple sclerosis; NFL; tau

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROFILAMENT LIGHT CHAIN PROTEIN; NEUROFILAMENT PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS;

EID: 84864150929     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511433303     Document Type: Article

References (53)

1. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000 ; 47: 707-717
2. Siva A. The spectrum of multiple sclerosis and treatment decisions. Clin Neurol Neurosurg. 2006 ; 108: 333-338
3. Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2007 ; 184: 37-44
4. Berger T, Reindl M. Multiple sclerosis: disease biomarkers as indicated by pathophysiology. J Neurol Sci. 2007 ; 259: 21-26
5. Imitola J, Chitnis T, Khoury SJ. Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol. 2006 ; 63: 25-33
6. Taupin P. Thirteen compounds promoting oligodendrocyte progenitor cell differentiation and remyelination for treating multiple sclerosis: WO2010054307. Exp Opin Ther Pat. 2010 ; 20: 1767-1773
7. Brück W, Schmied M, Suchanek G, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol. 1994 ; 35: 65-73
8. Lucchinetti CF, Brück W, Rodriguez M, et al. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol. 1996 ; 6: 259-274
9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996 ; 46: 907-911
10. Fiorini M, Zanusso G, Benedetti MD, et al. Cerebrospinal fluid biomarkers in clinically isolated syndromes and multiple sclerosis. Proteomics Clin Appl. 2007 ; 1: 963-971
11. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain. 2004 ; 127: 1463-1478
12. Ottervald J, Franzén B, Nilsson K, et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J Proteomics. 2010 ; 73: 1117-1132
13. Dumont D, Noben J-P, Raus J, et al. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics. 2004 ; 4: 2117-2124
14. Hammack BN, Fung KY, Hunsucker SW, et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler. 2004 ; 10: 245-260
15. Stoevring B, Vang O, Christiansen M. [alpha]B-crystallin in cerebrospinal fluid of patients with multiple sclerosis. Clin Chim Acta. 2005 ; 356: 95-101
16. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 ; 72: 1322-1329
17. Pål B-H, Bodvar V, Magne F, et al. Calprotectin levels in the cerebrospinal fluid reflect disease activity in multiple sclerosis. J Neuroimmunol. 2009 ; 216: 98-102
18. Sellebjerg F, Bornsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009 ; 73: 2003-2010
19. Wagner M, Naik D, Pothen A, et al. Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinform. 2004 ; 5: 26
20. Soman T, Bobbie P. Classification of arrhythmia using machine learning techniques. WSEAS Trans Comp. 2005 ; 4: 548-552
21. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005 ; 58: 840-846
22. Peterson GL. A simplification of the protein assay method of Lowry et al which is more generally applicable. Anal Biochem. 1977 ; 83: 346-356
23. Jiang L, He L, Fountoulakis M. Comparison of protein precipitation methods for sample preparation prior to proteomic analysis. J Chromatogr A. 2004 ; 1023: 317-320
24. Burnette WN. 'Western blotting': electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981 ; 112: 195-203
25. Kruger NJ The protein protocols handbook. Walker JM, ed. Humana Press ; 1996: 15-20.
26. Markus R, Sabrina K, Rainer E, et al. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuroimmunol. 2003 ; 145: 139-147
27. Lavrač N Artificial intelligence in medicine. Horn W Shahar Y Lindberg G, ed. Berlin/Heidelberg: Springer ; 1999: 47-62.
28. Freund Y, Schapire R, Abe N. A short introduction to boosting. J Jap Soc Art Intell. 1999 ; 14: 771-780
29. Hall M, Frank E, Holmes G, et al. The WEKA data mining software: an update. SIGKDD Explor Newsl. 2009 ; 11: 10-18
30. Larranaga P, Calvo B, Santana R, et al. Machine learning in bioinformatics. Brief Bioinform. 2006 ; 7: 86
31. Bradley AP. The use of the area under the ROC curve in the evaluation of machine learning algorithms. Patt Recog. 1997 ; 30: 1145-1159
32. Mazurowski MA, Habas PA, Zurada JM, et al. Training neural network classifiers for medical decision making: the effects of imbalanced datasets on classification performance. Neural Netw. 21: 427-436
33. Zaffaroni M. Biological indicators of the neurodegenerative phase of multiple sclerosis. Neurol Sci. 2003 ; 24: s279 - s282
34. Rostasy K, Withut E, Pohl D, et al. Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol. 2005 ; 20: 822-825
35. Martínez-Yélamos A, Saiz A, Bas J, et al. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis. Neurosci Lett. 2004 ; 363: 14-17
36. Kapaki E, Paraskevas GP, Michalopoulou M, et al. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol. 2000 ; 43: 228-232
37. Kosik K. Tau protein and neurodegeneration. Mol Neurobiol. 1990 ; 4: 171-179
38. Liedtke W, Edelmann W, Bieri PL, et al. GFAP Is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron. 1996 ; 17: 607-615
39. Eng LF. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol. 1985 ; 8: 203-214
40. Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci. 1995 ; 133: 61-65
41. Axelsson M, Malmeström C, Nilsson S, et al. J Neurol. 2010: 1-7
42. Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain. 2002 ; 125: 1462-1473
43. Lycke JN, Karlsson J-E, Andersen O, et al. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998 ; 64: 402-404
44. Malmeström C, Haghighi S, Rosengren L, et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003 ; 61: 1720-1725
45. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. New Engl J Med. 1998 ; 338: 278-285
46. Norgren N, Sundström P, Svenningsson A, et al. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004 ; 63: 1586-1590
47. Lalive PH, Menge T, Delarasse C, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA. 2006 ; 103: 2280-2285
48. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. New Engl J Med. 2003 ; 349: 139-145
49. Reder AT, Oger JJ. Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Neurology. 2004 ; 62: 1922-1923
50. Antel JP, Bar-Or A. Do myelin-directed antibodies predict multiple sclerosis?. New Engl J Med. 2003 ; 349: 107-109
51. Harauz G, Ishiyama N, Hill CMD, et al. Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron. 2004 ; 35: 503-542
52. Annunziata P, Pluchino S, Martino T, et al. High levels of cerebrospinal fluid IgM binding to myelin basic protein are associated with early benign course in multiple sclerosis. J Neuroimmunol. 1997 ; 77: 128-133
53. Chamczuk AJ, Ursell M, O'Connor P, et al. A rapid ELISA-based serum assay for myelin basic protein in multiple sclerosis. J Immunol Meth. 2002 ; 262: 21-27